Nongfu Spring Investment Quality Review (09633.HK)

Data timestamp: 2026-08-03 22:13 UTC
Quality score: 83/100
Valuation position: current price/base FV 1.77
Final signal: WATCHLIST

Core Conclusion

Nongfu Spring is high quality but materially over base fair value. HKD43.60 equals 1.77x base FV of HKD24.62 and 2.89x conservative FV of HKD15.10. The right stance is to admire the business and wait.

Business Breakdown

Five-year revenue CAGR is 18.7%, with latest-year revenue of CNY52.55bn. The bottled water and beverage platform has strong brand economics and distribution, but the market price already capitalizes much of the quality.

Business Quality

The 83/100 score is supported by strong profitability, scale, and cash generation. Latest-year FCF was CNY14.37bn. Five-year average ROE was 40.2% and average ROIC was 32.9%. The key constraint is valuation, not business quality.

Financial Audit

Fiscal 2025 revenue was CNY52.55bn, net profit CNY15.87bn, operating cash flow CNY21.14bn, capex CNY6.77bn, and FCF CNY14.37bn. Five-year FCF/net income was 0.86 and OCF/net income was 1.31. Latest net cash was CNY6.69bn.

Valuation

The conservative case uses CNY14.37bn normalized FCF, 2.0% growth, and 9.2x, producing HKD15.10. The base case uses 4.0% growth and 15.6x, producing HKD24.62. The optimistic case uses 5.0% growth and 20.0x, producing HKD31.15. Even the optimistic case is below the current price.

Buy And Tracking Discipline

The action is watch only. A buy requires price/base FV below 0.70, quality score above 75, repeatable cash conversion, and no signs that category growth, margins, or distribution economics are weakening.

Risk Review

Risks include category competition, price promotion, input-cost pressure, product-mix shifts, distribution disruption, and overpaying for quality. Two periods of weak FCF conversion or loss of net cash would reduce FV.

Data Sources

The memo relies on public market and financial data, company filings or investor-relations materials, ChinaBond yield data, and public FX data where applicable. This is research only, not personalized investment advice.